# Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)

> **NCT00047229** · PHASE2 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 27 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **BIOLOGICAL:** oblimersen sodium
- **DRUG:** doxorubicin hydrochloride

## Key facts

- **NCT ID:** NCT00047229
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2009-01
- **Final completion:** 2009-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2017-11-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00047229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00047229, "Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00047229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*